liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Individualiserad behandling vid ovarialcancer kan bli möjlig
Linköping University, Department of Clinical and Experimental Medicine, Division of Clinical Sciences. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Center of Paediatrics and Gynaecology and Obstetrics, Department of Gynaecology and Obstetrics in Linköping.
Kvinnosjukvården, Sahlgrenska universitetssjukhuset, Göteborg.
Onkologiska kliniken, Akademiska sjukhuset, Uppsala.
Linköping University, Department of Clinical and Experimental Medicine, Division of Clinical Sciences. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Center for Surgery, Orthopaedics and Cancer Treatment, Department of Oncology.
2015 (Swedish)In: Läkartidningen, ISSN 0023-7205, E-ISSN 1652-7518, Vol. 112, no 50, 2281-3 p.Article in journal (Refereed) Published
Abstract [en]

Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy in developed countries. Several promising steps toward individualized therapy have been taken recently due to increased knowledge of molecular biology. Multidisciplinary conferences for treatment planning and the centralization to tertiary surgical centers improve quality of surgery and survival. The primary treatment of EOC is radical surgery followed by adjuvant chemotherapy with carboplatin and paclitaxel. Bevacizumab added to the chemotherapy and used as maintenance treatment is standard in the primary treatment of patients with residual tumor or inoperable patients. The PARP inhibitor olaparib is recommended as maintenance treatment of women with platinum sensitive relapsed BRCA mutated high-grade serous EOC who have responded to platinum-based chemotherapy. BRCA testing should be offered to women with EOC. In platinum-resistant recurrence addition of bevacizumab to chemotherapy should be considered.

Abstract [sv]

Ovarialcancer har högst mortalitet bland gynekologiska cancersjukdomar. I Sverige insjuknar årligen ca 700 patienter. Överlevnaden är bland de högsta i Europa, men på en låg nivå, 46 procent.Nästan 90 procent av kvinnor-na har symtom även i tidigt stadium.Symtom som ska väcka misstanke om ovarialcancer är ihållande utspänd buk, tidig mättnadskänsla, bäcken- eller buksmärta, ökande urinträngningar och postmenopausal blödning.Kvinnors benägenhet att söka sjukvård och sjukvårdens organisation bidrar till canceröverlevnad.Ovarialcancer sammanfattarflera sjukdomar med skilda tumörkarakteristika och prognos. Individualiserad behandling och preventiva åtgärder utifrån denna nyvunna kunskap kan komma att inverka positivt på överlevnaden.

Place, publisher, year, edition, pages
2015. Vol. 112, no 50, 2281-3 p.
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:liu:diva-125273PubMedID: 26646960OAI: oai:DiVA.org:liu-125273DiVA: diva2:904385
Available from: 2016-02-18 Created: 2016-02-18 Last updated: 2016-02-29

Open Access in DiVA

No full text

Other links

PubMedläs hela artikeln

Search in DiVA

By author/editor
Kjölhede, PrebenÅvall Lundqvist, Elisabeth
By organisation
Division of Clinical SciencesFaculty of Medicine and Health SciencesDepartment of Gynaecology and Obstetrics in LinköpingDepartment of Oncology
In the same journal
Läkartidningen
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 255 hits
ReferencesLink to record
Permanent link

Direct link